Upstream Bio (NASDAQ: UPB) revenue
Upstream Bio reported revenue of $2.9m for fiscal 2025, 20.4% more than in fiscal 2024 ($2.4m). Since fiscal 2023 its revenue has grown by 19.9%, an average growth of 9.5% a year.
Fiscal 2025 is the highest of the 3 fiscal years on record for Upstream Bio. The biggest drop was in fiscal 2024, −0.4%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $2.9m | +20.4% | −$160.4m | −5,618.8% |
| 2024 | $2.4m | −0.4% | −$77.8m | −3,281.2% |
| 2023 | $2.4m | — | −$40.1m | −1,685.5% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Upstream Bio revenue compared with its sector
By revenue for its latest fiscal year, Upstream Bio ranks 389th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Upstream Bio, 20.4%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 387th | Surrozen | $3.5m | −67.4% |
| 388th | Onkure Therapeutics | $3.4m | 70.9% |
| 389th | Upstream Bio | $2.9m | 20.4% |
| 390th | Absci | $2.8m | −38.2% |
| 391st | Cartesian Therapeutics | $2.8m | −92.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Upstream Bio
- How much revenue did Upstream Bio make in fiscal 2025?
- Upstream Bio reported revenue of $2.9m for fiscal 2025, compared with $2.4m in fiscal 2024.
- How much has the revenue of Upstream Bio grown?
- Between fiscal 2023 and fiscal 2025 it went from $2.4m to $2.9m: 19.9% more, an average growth of 9.5% a year.
- What was the best year for revenue at Upstream Bio?
- Of its last 3 fiscal years, fiscal 2025, with $2.9m.
- Where does Upstream Bio rank in its sector by revenue?
- It ranks 389th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Upstream Bio come from?
- From the annual report (Form 10-K) that Upstream Bio files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Upstream Bio files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Upstream Bio: the Upstream Bio page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.